Several other research firms also recently weighed in on EVFM. HC Wainwright set a $11.00 price target on shares of Evofem Biosciences and gave the stock a buy rating in a research report on Monday, August 6th. Cantor Fitzgerald set a $9.00 price target on shares of Evofem Biosciences and gave the stock a buy rating in a research report on Wednesday. Finally, ValuEngine upgraded shares of Evofem Biosciences from a hold rating to a buy rating in a research report on Thursday, November 1st. Six equities research analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average price target of $10.40.
EVFM traded down $0.10 during trading on Wednesday, hitting $3.40. The company’s stock had a trading volume of 29,340 shares, compared to its average volume of 36,745. Evofem Biosciences has a one year low of $1.79 and a one year high of $12.90.
In other news, Director Thomas G. Lynch acquired 100,000 shares of Evofem Biosciences stock in a transaction dated Wednesday, August 15th. The stock was purchased at an average cost of $2.26 per share, with a total value of $226,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired 108,000 shares of company stock worth $243,770 over the last quarter. Insiders own 3.40% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Heartland Advisors Inc. purchased a new stake in shares of Evofem Biosciences in the third quarter worth $1,319,000. Millennium Management LLC increased its stake in shares of Evofem Biosciences by 6,497.4% in the second quarter. Millennium Management LLC now owns 733,765 shares of the biotechnology company’s stock worth $1,989,000 after purchasing an additional 722,643 shares in the last quarter. Finally, Woodford Investment Management Ltd increased its stake in shares of Evofem Biosciences by 28.5% in the second quarter. Woodford Investment Management Ltd now owns 9,593,197 shares of the biotechnology company’s stock worth $25,998,000 after purchasing an additional 2,127,659 shares in the last quarter. 79.29% of the stock is owned by hedge funds and other institutional investors.
About Evofem Biosciences
Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.
Further Reading: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.